HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin

Cancer Treat Res. 2007;134:303-18. doi: 10.1007/978-0-387-48993-3_19.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Camptothecin / pharmacokinetics
  • Carcinoma / drug therapy*
  • Carcinoma / mortality
  • Carcinoma / secondary
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / surgery
  • Drug Therapy / methods
  • Female
  • Humans
  • Hyperthermia, Induced*
  • Infusions, Parenteral / methods*
  • Irinotecan
  • Male
  • Organoplatinum Compounds / administration & dosage*
  • Organoplatinum Compounds / pharmacokinetics
  • Oxaliplatin
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / secondary
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin
  • Irinotecan
  • Camptothecin